Similar Items: Drug discovery at the site of pulmonary tuberculosis
- Barriers to tuberculosis drug discovery: the mycobacterial cell wall
- Investigating the chemical diversity and biomedicinal potential of South African actinomycetes for tuberculosis drug discovery
- Investigating permeation of anti-mycobacterial agents in Mycobacterium tuberculosis and M. tuberculosis-infected macrophages in vitro as a model for early stage tuberculosis drug discovery
- Exploring the molecular diversity and biomedicinal potential of marine invertebrates and South African actinomycetes for tuberculosis drug discovery
- Development of a drug discovery protocol through the expression of key mycothiol biosynthetic enzymes for Mycobacterium tuberculosis
- Genotypic and phenotypic diversity of Mycobacterium tuberculosis strains in patients with concomitant pulmonary and extra-pulmonary tuberculosis
Author: Wiesner, Lubbe
- Development and validation of selective and sensitive LC-MS/MS Methods for determination of para-aminosalicyclic acid and cycloserine/terizidone applicable to clinical studies for the treatment of tuberculosis
- Determination of total, unbound, and intracellular concentrations of the antiretroviral drugs Efavirenz, Lopinavir, and Ritonavir
- Screening rare filamentous actinobacteria for novel antimycobacterial compounds
- Simultaneous quantification of first-line anti-tuberculosis drugs and metabolites in human plasma
- A pharmacokinetic and antimalarial efficacy evaluation of pyridodibemequines and their metabolites
- Isolation and characterisation of antiplasmodial compounds from Xerophyta species and the bioavailability, metabolic and efficacy evaluation of 9-0-acetylhydnocarpin in a mouse model